SEARCH

SEARCH BY CITATION

References

  • References to studies included in this review
  • Barthelemy 1989 {published data only}
  • * Barthelemy C, Bruneau N, Jouve J, Martineau J, Muh JP, Lelord G. Urinary dopamine metabolites as indicators of the responsiveness of fenfluramine treatment in children with autistic behavior. Journal of Autism and Developmental Disorders 1989;19(2):241-54.
  • Buchsbaum 2001 {published data only}
  • * Buchsbaum M, Hollander E, Haznedar M, Tong C, Spiegal-Cohen J, Wei T, et al.Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. International Journal of Neuropsychopharmacology 2001;4:119-25.
  • Hollander 2005 {published data only}
  • * Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-9.
  • King 2009 {published data only}
  • King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al.Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry 2009;66(6):583-90.
  • Leventhal 1993 {published data only}
  • * Leventhal B, Cook E, Morford M, Ravitz A, Heller W, Freedman D. Clinical and neurochemical effects of fenfluramine in children with autism. Journal of Neuropsychiatry 1993;5(3):307-15.
  • McDougle 1996 {published data only}
  • * McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 1996;53(11):1001-8.
  • Sugie 2005 {published data only}
  • * Sugie Y, Sugie H, Kukuda T, Ito M, Sasada Y, Nakabayashi M, et al.Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders 2005;35(3):377-85.
  • References to studies excluded from this review
  • Doyle 2001 {published data only}
  • Doyle J, Casciano J, Arikan S, Tarride J-E, Gonzales M, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health 2001;4(1):16-31.
  • Gordon 1993 {published data only}
  • * Gordon C, State R, Nelson J, Hamburger S, Rapoport J. A double-blind comparison of clomipramine, desipramine, and of autistic disorder. Archives of General Psychiatry 1993;50(6):441-7.
  • Humble 2001 {published data only}
  • Humble M, Bejerot S, Bergqvist P, Bengtsson F. Reactivity of serotonin in while blood: relationship with drug response in obsessive-compulsive disorder. Biological Psychiatry 2001;49:360-8.
  • McDougle 1998 {published data only}
  • McDougle C, Brodkin E, Naylor S, Carlson D, Cohen D, Price L. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. Journal of Clinical Psychopharmacology 1998;18(1):62-6.
  • Peral 1999 {published data only}
  • Peral M, Alcami M, Gilaberte I. Fluoxetine in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry 1999;38(12):1472-3.
  • Remington 2001 {published data only}
  • * Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, cross-over study. Journal of Clinical Psychopharmacology 2001;21(4):440-4.
  • Sanchez 1996 {published data only}
  • Sanchez L, Campbell M, Small A, Cueva J, Armenteros J, Adams P. A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(4):537-44.
  • Additional references
  • Aman 2005
  • Aman MG, Lam KSL, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of Child & Adolescent Psychopharmacology 2005;15(1):116-26.
  • APA 1980
  • Diagnostic and Statistical Manual of Mental Disorders. Third Edition. American Psychiatric Association, 1980.
  • APA 1987
  • Diagnostic and Statistical Manual of Mental Disorders. Revised third. American Psychiatric Association, 1987.
  • APA 1994
  • Diagnostic and Statistical Manual of Mental Disorders. Fourth. American Psychiatric Association, 1994.
  • APA 2000
  • Diagnostic and Statistical Manual of Mental Disorders. Text revision - fourth. American Psychiatric Association, 2000.
  • Atladottir 2007
  • Atladottir HO, Parner ET, Schendel D, Dalsgaard S, Thomsen PH, Thorsen P. Time trends in reported diagnoses of childhood neuropsychiatric disorders: A Danish cohort study. Archives of Pediatric & Adolescent Medicine 2007;161(2):193-8.
  • Baird 2006
  • Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al.Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006;368(9531):210-5.
  • Billstedt 2005
  • Billstedt E, Gillberg IC, Gillberg C. Autism after adolescence: population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. Journal of Autism & Developmental Disorders 2005;35:351-60.
  • Bodfish 1999
  • Bodfish JW, Symons FW, Lewis MH. The Repetitive Behavior Scale. Morganton, NC: Western Carolina Center Research Reports, 1999.
  • Branford 1998
  • Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. Journal of Intellectual Disability Research 1998;42(4):301-6.
  • Chen 2007
  • Chen C-Y, Liu C-Y, Su W-C, Huang S-L, Lin K-M. Factors associated with the diagnosis of neurodevelopmental disorders: A population-based longitudinal study. Pediatrics 2007;119(7):e435-43.
  • Clarke 2003
  • Clarke M, Oxman AD (editors). Cochrane Handbook for Systematic Reviews of Interventions. Oxford: Update Software, 2003.
  • Cook 1996
  • Cook EH, Leventhal BL. The serotonin system in autism. Current Opinion in Pediatrics 1996;8:348-54.
  • Fombonne 2006
  • Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. Pediatrics 2006;118:e139-50.
  • Gillberg 2006
  • Gillberg C, Cederlund M, Lamberg K, Zeijlon L. Brief report: The "Autism Epidemic". The registered prevalence of autism in a Swedish urban area. Journal of Autism and Developmental Disorders 2006;26(3):429-35.
  • Goodman 1989
  • Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger, GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 1989;46(11):1012-16.
  • Goodman 1989b
  • Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman RL, Hill CL, Heninger, GR, Charney DS. The Yale-Brown Obsessive Compuslive Scale. I. Development, Use, and Reliability. Archives of General Psychiatry 1989;46:1006-11.
  • Greenhill 2004
  • Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff H, et al.Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(12):1488-96.
  • Gringras 2000
  • Gringras P. Practical paediatric psychopharmacological prescribing in autism. Autism 2000;4(3):229-47.
  • Guillem 2006
  • Guillem P, Cans C, Guinchat V, Ratel M, Jouk P-S. Trends, perinatal characteristics, and medical conditions in pervasive developmental disorders. Developmental Medicine & Child Neurology 2006;48(11):896-900.
  • Guy 1976
  • Guy W. ECDEU Assessment Manual for Psychopharmacology. Vol. NIMH Publication DHEW Publ No. 76-388, Bethesda, MD: National Institute of Mental Health, 1976.
  • Higgins 2002
  • Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
  • Higgins 2008
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
  • Howlin 2004
  • Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. Journal of Child Psychology & Psychiatry & Allied Disciplines 2004;45:212-29.
  • Jesner 2007
  • Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews 2007, Issue 1.
  • McCracken 2002
  • McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al.Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002;347(5):314-21.
  • McKay 2003
  • McKay D, Piacentinib J, Greisberga S, Graaec F, Jafferc M, Millerc J, Neziroglud F, Yaryura-Tobiasd JA. The Children's Yale-Brown Obsessive-Compulsive Scale: Item Structure in an Outpatient Setting. Psychological Assessment 2003;15(4):578-81.
  • Murray 2005
  • Murray ML, Wong ICK, Thompson M. Do selective serotonin reuptake inhibitors cause suicide? Antidepressant prescribing to children and adolescents by GPs has fallen since CSM advice (Letter). BMJ  2005;330(7500):1151.
  • Nemeroff 2007
  • Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, et al.Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry 2007;64(4):466-72.
  • Saxena 1995
  • Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacology and Therapeutics 1995;66(2):339-68.
  • Scahill 2006
  • Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al.The Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(9):1114-23.
  • Sinha 2004
  • Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders. Cochrane Database of Systematic Reviews 2004, Issue 1.
  • WHO 1993
  • World Health Organisation. International Classification of Diseases. International Classification of Diseases (ICD-10). World Health Organisation, 1993.
  • Williams 2005
  • Williams KJ, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database of Systematic Reviews 2005, Issue 3.
  • Williams 2006
  • Williams JG, Higgins JPT, Brayne CEG. Systematic review of prevalence studies of autism spectrum disorders. Archives of Diseases in Childhood 2006;91:8-15. [DOI: 10.1136/adc.2004.062083]
  • Williams 2008
  • Williams K, Macdermott S, Ridley G, Glasson EJ, Wray JA. The prevalence of autism in Australia. Can it be established from existing data?. Journal of Paediatrics and Child Health 2008;44(9):504-10.